-

Global Vitreo Retinal Surgery Devices Pipeline Report 2022 Update: Formulate Significant Competitor Information, Analysis, and Insights to Improve R&D Strategies - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Vitreo Retinal Surgery Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update" report has been added to ResearchAndMarkets.com's offering.

The report enables you to:

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Identify and understand important and diverse types of Vitreo Retinal Surgery Devices under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Scope

  • Extensive coverage of the Vitreo Retinal Surgery Devices under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Vitreo Retinal Surgery Devices and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved/Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment/industry

Key Topics Covered:

1 Table of Contents

2 Introduction

3 Products under Development

3.1 Vitreo Retinal Surgery Devices - Pipeline Products by Stage of Development

3.2 Vitreo Retinal Surgery Devices - Pipeline Products by Territory

3.3 Vitreo Retinal Surgery Devices - Pipeline Products by Regulatory Path

3.4 Vitreo Retinal Surgery Devices - Pipeline Products by Estimated Approval Date

3.5 Vitreo Retinal Surgery Devices - Ongoing Clinical Trials

4 Vitreo Retinal Surgery Devices - Pipeline Products under Development by Companies

4.1 Vitreo Retinal Surgery Devices Companies - Pipeline Products by Stage of Development

4.2 Vitreo Retinal Surgery Devices - Pipeline Products by Stage of Development

5 Vitreo Retinal Surgery Devices Companies and Product Overview

5.1 ABVC BioPharma Inc Company Overview

5.2 AcuSurgical Company Overview

5.3 Alcon Inc Company Overview

5.4 Bausch & Lomb Inc Company Overview

5.5 Beaver-Visitec International Inc Company Overview

5.6 Boston College Company Overview

5.7 Cambridge Polymer Group Inc Company Overview

5.8 Carnegie Mellon University Company Overview

5.9 Duke University Company Overview

5.10 Dutch Ophthalmic Research Center International BV Company Overview

5.11 Johns Hopkins University Company Overview

5.12 King's College London Company Overview

5.13 Medisse BV (Inactive) Company Overview

5.14 RetinaSense Company Overview

5.15 Synergetics USA, Inc. (Inactive) Company Overview

5.16 The Chinese University of Hong Kong Company Overview

5.17 University of Kansas Company Overview

5.18 University of Minnesota Company Overview

6 Vitreo Retinal Surgery Devices- Recent Developments

7 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/zd122m

Source: GlobalData

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Research and Markets


Release Versions

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

More News From Research and Markets

Blockchain and Non-Fungible Tokens new Technologies and the Relevant Law Training Course: Core Principles, Smart Contracts, NFTs, and Decentralized Finance Explained (Online Event: May 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Blockchain and Non-Fungible Tokens: Understanding new Technologies and the Relevant Law Training Course (May 20, 2026)" training has been added to ResearchAndMarkets.com's offering. Blockchain is a new technology that could potentially have major impacts in a wide range of industries. It has the potential to dramatically change how business is conducted - but there is no one central authority controlling blockchain, everyone has access to the same information. Are...

Writing Clinical Research with Integrity Training Course: Principles of Medical and Scientific Writing, Including Ethical Standards, Data Integrity, and Plagiarism Prevention (Online: Apr 20, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Writing Clinical Research with Integrity Training Course (Apr 20, 2026)" training has been added to ResearchAndMarkets.com's offering. This course covers key principles of medical and scientific writing, including ethical standards, data integrity, and plagiarism prevention. Participants will learn how to tailor content for various audiences, structure documents (e.g., manuscripts, protocols), and adhere to writing standards such as clarity, consistency, and correc...

In-Vitro Diagnostic Regulation (EU) 2017/746 Introduction Training Course (Online Event: Apr 16th - Apr 17th, 2026) - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Introduction to the In-Vitro Diagnostic Regulation (IVDR) Training Course (Apr 16th - Apr 17th, 2026)" training has been added to ResearchAndMarkets.com's offering. The In-Vitro Diagnostic Regulation (EU) 2017/746, which came into force in May 2017 with a transition period of five years, is intended to strengthen the current approval system for in-vitro diagnostics and makes substantial changes to the existing IVD Directive (98/79/EC) legislation. The Regulation in...
Back to Newsroom